A phase I clinical trial on the use of autograft mesenchymal stem cells for treatment of diabetic chronic kidney disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT138804091267N19

Enrollment

Registered

2009-07-14

Start date

2008-09-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy. Diabetic nephropathy

Interventions

Injection of separated mesenchymal stem cells to the patient’s peripheral vein.

Treatment - Other

Injection of separated mesenchymal stem cells to the patient’s peripheral vein

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of stage III diabetic nephropathy (GFR between 30 to 60 ml / min /1.73 m2), controlled hypertension, Blood creatinine level less than 2 mg/dl Exclusion criteria: History or presence of psychological disorders, history or presence of previous immune deficiencies, consumption of immunosuppressive drugs, presence of renal artery stenosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Kidney function. Timepoint: one year after injection. Method of measurement: Bun, Cr.	—

Secondary

Measure	Time frame
Complication. Timepoint: to one year. Method of measurement: Billirubin.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDR Naser Shakhssalim

Urology and Nephrology Research Center ( UNRC), Shahid Beheshti University, M.C.( SBMU), Tehran, I.

research@unrc.ir+98 21 2256 7222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026